Publications

2021

Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F, Sung EK. UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth. PNAS. 2021; In press

Loats AE, Carrera S, Fleming AF, Rorberts AR, Sherrard A, Toska E, Moorhouse AJ, Medler K, Roberts SG. Cholesterol is required for transcriptional repression by BASP1. PNAS. 2021; In press

Castel P, Toska E, Engelman JA*, Scaltriti M*. The present and future of PI3K inhibitors in solid tumors. Nature Cancer. 2021; Accepted. Equal contribution, *Corresponding

Arruabarrena-Aristorena A* and Toska E*. FOXA1 mutations influence the therapeutic response of breast cancer by altering chromatin state. 2021. Molecular and Cellular Oncology. In press *Corresponding

Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X, Selenica P, Ladewig E, Castel P, Cheng Y, Zhao A, Jhaveri K, Toska E, Jimenes M, Jacquet A, Tran-Dien A, Andre F, Chandarlapaty S, Reis-Filho JS, Razavi P, Scaltriti M. Genomic alterations in PIK3CA-mutated breast cancer results in mTORC1 activation and limit sensitivity to PI3Ka inhibitors. Cancer Research 2021. In press

2020

Cocco E, Lee Ji, Kannan S, Schram A, Won H, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick A, Berger M, Novoplansky O, Jagadeeshan S, Lao Y, Rix U, Misale S, Taylor B, Bardelli A, Hechtman J, Hyman D, Elkabets M, de Stanchina E, Verma C, Ventura A, Drilon A, Scaltriti M. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. Cancer Discovery. 2020. In press

Arruabarrena-Aristorena A, Maag J, Kittane S, Cai Y, Karthaus W, Park J, Razavi P, Ferrando L, Kannan S, Selenica P, Cocco E, Ho S, Tan D, Sallaku M, Witkin M, Sawyers C, Reis-Filho J, Verma CS, Jauch R, Koche R, Baselga J, Toska E*, Scaltriti M*. FOXA1 mutations reveal distinct chromatin profiles and influences therapeutic response in breast cancer. Cancer Cell. 2020; S1535-6108(20)30414-1 *Corresponding

Mondello P, Tadros S, Teater M, Fontan L, Chang A, Jain N, Yang H, Singh S, Ying H, Chu C, Ma M, Toska E, Alig S, Durant M, Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelpau S, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg D, Roeder R, Melnick A*, Green M*. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery. 2020; 10(3):440-459

Xu G, Chhangawala S, Cocco E, Razavi P, Casi Y, Otto J, Ferrando L, Selenica P, Chan C, Ladewig E, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, Zhao H, Wu F, Sallaku M, Qu X, Zhao A, Collings C, D’Avino AR, Jhavery K, Koche R, Levine RL, Reis-Filho JS, Kadoch C, Scaltriti M, Leslie CS*, Baselga J*, Toska E*. ARID1A determines luminal identity and therapeutic response in estrogen receptor-positive breast cancer. Nature Genetics. 2020; 52(2):198-207 Equal contribution, *Corresponding

2019

Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Annals of Oncology. 2019. Equal contribution

Toska E*, Castel P, Chhangawala S, Arruabarrena-Aristorena A, Chan C, Hristidis VC, Cocco E, Sallaku M, Xu G, Park J, Minuesa G, Shifman SG, Socci ND, Koche R, Leslie CS, Scaltriti M, Jose Baselga*. PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression. Cell Reports. 2019; 27(1):294-306. *Corresponding

Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hecktman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selcuklu SD, Samonika A, Guzman S, Tuch BB, Ebata K, de Stanchina E, Nagy RJ, Lanman RB, Houck-Loomis B, Patel JA, Berger MF, Ladanyi M, Hyman DM, Drilon A, Scaltriti M. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. 2019; 25(9):1422-1427

Vasan N, Razavi P, Johnson J, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang M, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M*, Jose Baselga*. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors. Science. 2019; 366(6466):714-723 Equal Contribution.

Castel P, Toska E*. Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer. Molecular and Cellular Oncology. 2019; 6(6):e1625620 *Corresponding

2018

Cocco E, Carmona JF, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Advogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltritri M. Neratinib is effective I breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling. 2018; 11(551)

2017

Toska E, Osmanbeyoglu H, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler M, Scaltriti M, Leslie CS, Armstrong SA, Baselga. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017; 355(6331):134-1330

Mondello P, Brea E, de Stanchina E, Toska E, Chang A, Fennel M, Seshan V, Garippa R, Scheinberg D, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse B-cell lymphoma cells with MyD88 L265 mutations. Journal of Clinical Investigations. 2017; 2(6):e90196

Osmanbeyoglu HU, Toska E, Chan C, Baselga J, Leslie CS. Modeling the impact of somatic alterations on signaling pathways and transcriptional programs in human cancers. Nature Communications. 2017; 1:14249

Perovic V, Sumonja N, Gemovic B, Toska E, Roberts SG, Veljkovic N. TRI_tool: a web-tool for prediction of protein-protein interactions in human transcriptional regulation. Bioinformatics. 2017; 33(2):289-291

2016

Toska E, Baselga J. Pharmacology in the era of targeted therapies: the case of PI3K inhibitors. Clinical Cancer Research. 2016; 22(9):2099-101

Castel P, Ellis H, Bago, Ruzica, Toska E, Srinivasaraghavan K, Carmona FJ, Razavi P, Verma CS, Dickler M, Chandaralapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Ka inhibition. Cancer Cell. 2016; 30(2):229-42

2015

Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodon J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor positive breast cancer. Science Translational Medicine. 2015; 7(283):283ra51

2014

Toska E, Shandilya J, Medler KF, Goodfellow SJ, Roberts SGE. Prohibitin is required for transcriptional repression by the WT1-BASP1 complex. Oncogene. 2014; 10.1038/onc.2013.447

Busch M, Schwindt H, Brandt A, Beier M, Gorld N, Romaniuk P, Toska E, Roberts SGE, Royer HD, Royer-Pokora B. Classification of a frameshift/extended and a stop mutation in WT1 as gain of function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation. Human Molecular Genetics. 2014; 10.1093/hmg/ddu111

Gao Y, Toska E, Denmon D, Roberst SGE, Medler KF. WT1 regulates the development of the posterior taste field. Development. 2014; 10.1242/dev.105676. Equal contribution

Shandilya J, Toska E, Richard RJ, Medler KF, Roberts SGE. WT1 interacts with Mad2 and regulates mitotic checkpoint function. Nature Communications. 2014; 10.1038/ncomms5903

Toska E, Roberts SGE. Mechanisms of transcriptional regulation by Wilms tumor 1 (WT1). Biochemical Journal. 2014; 10.1042/BJ20131587

Castel P, Toska E, Zumsteg Z, Carmona J, Elkabets M, Bosch A, Scaltriti M. Rationale-based therapeutic combination with PI3K inhibitors in cancer. Molecular and Cellular Oncology. 2014; 1(3):3963447. Equal contribution

2013

Kunsang D, Iacobucci GJ, Zheng KH, Shandilya J, Toska E, White JA, Spina E, Gunawardena S. Presenilin influences glycogen synthase kinase-3beta (GSK-3β) for kinesin-1 and dynein function during axonal transport. Human Molecular Genetics. 2013; doi: 10.1093/hmg/ddt505

2012

Toska E, Campbell HA, Shandilya J, Goodfellow SJ, Shore P, Medler KF, Roberts SG. Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase. Cell Reports. 2012; 2(3):462-9

2011

Goodfellow SJ, Revello MR, Toska E, Zeef L, Rudd S, Medler KF, Roberts SGE. WT1 and its transcriptional cofactor  BASP1 redirect the differentiation pathway of an established blood cell line. Biochemical Journal. 2011; 435(1):113-25